Skip to main content
Fig. 3 | Malaria Journal

Fig. 3

From: Risk factors for non-participation in ivermectin and dihydroartemisinin-piperaquine mass drug administration for malaria control in the MASSIV trial

Fig. 3

Overall treatment frequency and pattern for the dihydroartemisinin-piperaquine (DHP) MDA excluding non-eligible participants. Full points indicate MDA received. DPD# denotes the number of doses of DHP received, and the pattern such as a single dose or all nine MDA rounds. Certain patterns, such as received 1st and 9th MDA but none in between are excluded for convenience, therefore data for only 2855/3290 participants are shown

Back to article page

Malaria Journal

ISSN: 1475-2875

Contact us